EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Valganciclovir Underdosing Is Associated With Cytomegalovirus DNAemia During Universal Prophylaxis: A Real‐Life Case Control Retrospective Study

Pierre-Antonin Rigon iD, Justine Solignac, Christine Zandotti, Marion Gully, Philippe Brunet, Noémie Resseguier, Tristan Legris, Valérie Moal

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70666 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Pierre-Antonin Rigon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Assistance Publique-Hôpitaux de Marseille, Hôpital Conception, Centre de Néphrologie et Transplantation Rénale, Marseille, France. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Valganciclovir, Antiviral Agents, Kidney Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Universal prophylaxis or a preemptive strategy with valganciclovir (VGCV) is recommended for prevention of cytomegalovirus (CMV) infections after kidney transplantation. We combined both strategies during the first 3 months post‐transplantation. The objectives were to define the incidence of CMV DNAemia and identify the associated factors during universal prophylaxis in a retrospective monocentric case‐control study. Cases presenting CMV DNAemia during the first 3 months post‐transplantation were matched to four controls each regarding sex, age, donor and recipient CMV serostatus, and induction treatment. We collected the rates of visits with VGCV underdosing, comparing the adjusted daily dosage to the kidney function and the received daily dosage. Despite prophylaxis, the incidence of CMV DNAemia was 5.1% between 2017 and 2020 in 300 patients. Rates of visits with VGCV underdosing during follow‐up were significantly higher in the cases group than in the controls group. In the cases group, the rate was higher when using estimated creatinine clearance rather than estimated glomerular filtration rate. VGCV underdosing was the only factor associated with CMV DNAemia in the multivariate analysis (OR: 1.04 95% CI: 1.011–1.061, p = 0.003), regardless of the formula used to estimate kidney function. Resistance to GCV was observed in 4 out of 15 cases, two of which had VGCV underdosing. In our study, CMV DNAemia was associated with VGCV underdosing that could be related to the absence of systematic adjustment during post‐transplantation follow‐up or to the use of inadequate kidney function assessment formulas to adjust VGCV dosages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsValganciclovirAntiviral AgentsKidney TransplantationCytomegalovirusDNA, ViralViremiaHumansRetrospective StudiesMaleFemaleCase-Control StudiesMiddle AgedAdultIncidenceAged

Stichwörter der Autor:innen

CMVbreakthrough cytomegalovirus infectioncytomegaloviruskidney transplantationprophylaxisvalganciclovir

Substanzen

ValganciclovirAntiviral AgentsDNA, Viral

Autor:innen und Institutionen

  • Assistance Publique-Hôpitaux de Marseille, Hôpital Conception, Centre de Néphrologie et Transplantation Rénale, Marseille, France.
  • Aix-Marseille Université, Marseille, France.
  • Assistance Publique-Hôpitaux de Marseille, Service de Virologie Aiguë et Tropicale, Marseille, France.
  • CEReSS/UR 3279-Health Services and Quality of Life Research, Aix Marseille University, Marseille, France.
  • Methodological Support Unit for Clinical and Epidemiological Research, University Hospital of Marseille, Marseille, France.

ORCID-Profile: Pierre-Antonin Rigon

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Rigon, P. A., Solignac, J., Zandotti, C., Gully, M., Brunet, P., Resseguier, N., Legris, T., & Moal, V. (2025). Valganciclovir Underdosing Is Associated With Cytomegalovirus DNAemia During Universal Prophylaxis: A Real‐Life Case Control Retrospective Study. Journal of Medical Virology. https://doi.org/10.1002/jmv.70666

Vancouver

Rigon PA, Solignac J, Zandotti C, Gully M, Brunet P, Resseguier N, et al. Valganciclovir Underdosing Is Associated With Cytomegalovirus DNAemia During Universal Prophylaxis: A Real‐Life Case Control Retrospective Study. Journal of Medical Virology. 2025. doi:10.1002/jmv.70666

BibTeX
@article{Rigon2025,
  author = {Rigon, Pierre-Antonin and Solignac, Justine and Zandotti, Christine and Gully, Marion and Brunet, Philippe and Resseguier, Noémie and Legris, Tristan and Moal, Valérie},
  title = {Valganciclovir Underdosing Is Associated With Cytomegalovirus DNAemia During Universal Prophylaxis: A Real‐Life Case Control Retrospective Study},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70666}
}
Kostenlos starten →